Muğlu, H. Et Al. 2025. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.. Cancers , vol.17, no.9 .

Muğlu, H., Helvacı, K., Köylü, B., Yücel, M. H., Celayir, Ö. M., Demirci, U., ... Uluç, B. O.(2025). The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.. Cancers , vol.17, no.9.

Muğlu, Harun Et Al. "The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.," Cancers , vol.17, no.9, 2025

Muğlu, Harun Et Al. "The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.." Cancers , vol.17, no.9, 2025

Muğlu, H. Et Al. (2025) . "The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.." Cancers , vol.17, no.9.

@article{article, author={Harun Muğlu Et Al. }, title={The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.}, journal={Cancers}, year=2025}